Erschienen in:
01.05.2020 | Breast Cancer (B Overmoyer, Section Editor)
Applying the New Guidelines of HER2 Testing in Breast Cancer
verfasst von:
Huina Zhang, Ioana Moisini, Rana M. Ajabnoor, Bradley M. Turner, David G. Hicks
Erschienen in:
Current Oncology Reports
|
Ausgabe 5/2020
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
The human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive biomarker in the breast cancer. The American Society of Clinical Oncology/College of American Pathology (ASCO/CAP) has published HER2 testing guidelines in breast cancer. We herein reviewed the HER2 testing guidelines in breast cancer with a focus on the application of the current guidelines.
Recent Findings
The continual investigation of HER2 testing in breast cancer has resulted in updates in the HER2 testing guidelines. The current guidelines focus on the uncommon clinical scenarios and emphasize the coordination between immunohistochemistry and in situ hybridization results, in an effort to improve clarity and accuracy.
Summary
The ASCO/CAP guidelines provide valuable recommendations to ensure the accurate evaluation of HER2 status in breast cancer patients through standardization. Additional studies, particularly those with long-term outcome data are still needed to validate the guideline recommendations, especially the uncommon cases.